GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Cyclically Adjusted PS Ratio

Exelixis (Exelixis) Cyclically Adjusted PS Ratio : 7.96 (As of Apr. 29, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Exelixis Cyclically Adjusted PS Ratio?

As of today (2024-04-29), Exelixis's current share price is $23.73. Exelixis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $2.98. Exelixis's Cyclically Adjusted PS Ratio for today is 7.96.

The historical rank and industry rank for Exelixis's Cyclically Adjusted PS Ratio or its related term are showing as below:

EXEL' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.14   Med: 10.64   Max: 30.7
Current: 7.97

During the past years, Exelixis's highest Cyclically Adjusted PS Ratio was 30.70. The lowest was 1.14. And the median was 10.64.

EXEL's Cyclically Adjusted PS Ratio is ranked worse than
60.67% of 506 companies
in the Biotechnology industry
Industry Median: 5.395 vs EXEL: 7.97

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Exelixis's adjusted revenue per share data for the three months ended in Dec. 2023 was $1.532. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.98 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exelixis Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Exelixis's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Cyclically Adjusted PS Ratio Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.95 13.47 10.32 6.83 8.06

Exelixis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.83 7.75 7.16 7.71 8.06

Competitive Comparison of Exelixis's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Exelixis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Exelixis's Cyclically Adjusted PS Ratio falls into.



Exelixis Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Exelixis's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=23.73/2.98
=7.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Exelixis's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.532/129.4194*129.4194
=1.532

Current CPI (Dec. 2023) = 129.4194.

Exelixis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.026 99.695 0.034
201406 0.034 100.560 0.044
201409 0.032 100.428 0.041
201412 0.038 99.070 0.050
201503 0.048 99.621 0.062
201506 0.041 100.684 0.053
201509 0.045 100.392 0.058
201512 0.044 99.792 0.057
201603 0.068 100.470 0.088
201606 0.158 101.688 0.201
201609 0.243 101.861 0.309
201612 0.269 101.863 0.342
201703 0.261 102.862 0.328
201706 0.318 103.349 0.398
201709 0.487 104.136 0.605
201712 0.383 104.011 0.477
201803 0.681 105.290 0.837
201806 0.596 106.317 0.726
201809 0.722 106.507 0.877
201812 0.734 105.998 0.896
201903 0.685 107.251 0.827
201906 0.763 108.070 0.914
201909 0.861 108.329 1.029
201912 0.763 108.420 0.911
202003 0.718 108.902 0.853
202006 0.816 108.767 0.971
202009 0.748 109.815 0.882
202012 0.845 109.897 0.995
202103 0.841 111.754 0.974
202106 1.193 114.631 1.347
202109 1.020 115.734 1.141
202112 1.396 117.630 1.536
202203 1.101 121.301 1.175
202206 1.291 125.017 1.336
202209 1.267 125.227 1.309
202212 1.305 125.222 1.349
202303 1.253 127.348 1.273
202306 1.436 128.729 1.444
202309 1.478 129.860 1.473
202312 1.532 129.419 1.532

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exelixis  (NAS:EXEL) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Exelixis Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Exelixis's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (Exelixis) Business Description

Industry
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum director C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb officer: EVP, Discovery Research & CSO PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083

Exelixis (Exelixis) Headlines

From GuruFocus